Who is BlueRock?
BlueRock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company using its unique cell+gene platform to direct cellular differentiation and genetically engineer cells to create a new generation of cellular medicines that address large patient populations suffering from neurological, cardiovascular, and immunology diseases.
The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.
What Are We Doing?
Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit.
We are passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with treatment options.
We are seeking individuals who are collaborative, thrive in a fun and dynamic culture, and are steadfast in the commitment to advance cutting-edge cellular therapies to impact patients’ lives.
Description of Position:
The New York, USA site is seeking a Research Associate for the Genome Engineering pipeline that will be reporting to the Senior Scientist of the team.
The incumbent will be a technical contributor in a dynamic and progressive team pioneering the generation of genome-modified therapeutic cells from human pluripotent stem cells (hPSCs). Together with technical staff and direction from the Senior Scientist, the individual will contribute to the design and execution of a variety of genetic modifications that enhance cellular properties. This will include the employment of gene editing technologies including homologous recombination and CRISPR/Cas to establish cell lines for BlueRock’s research pipeline that are altered in their genome to provide novel morphology or function.
Responsibilities:
Requirements